Was this a short and distort story on a company that was later acquired by Gilead ($GILD) for $21 Billion. $88 a share? 

Immunomedics' breast cancer data was so good that the company was bought for $21 Billion in 2020 

But before being acquired the  company was selected to be the lead presenter at the ASCO Conference in 2016. 

Around 10pm the night before the conference Adam Feuerstein posted a story raising questions about Immunomedics'  data 

The company didn't have a chance to respond because it was the lead presenter at 8am. 

ASCO had no chance to investigate the claims so it removed Immunomedics as a presenter. 

Turns out the data was so good that Immunomedics was later acquired by Gilead. 

Now read the way this 2016 story is written. 

The Headline: 
"Immunomedics Kicked Out of Prestigious ASCO Cancer Conference" 

"Immunomedics was caught trying to sneak old, previously presented clinical data on its triple-negative breast cancer drug IMMU-132 into the American Society of Clinical Oncology (ASCO) annual meeting...."

"... sneak old, previously presented clinical data..."

Really?? A company that was acquired for $21 Billion was sneaking in old data??

Why did Adam Feuerstein write the story about Immunomedics this way? 

What happened to the stock price after the article came out? 

What would have happened to the stock price if that data was allowed to be presented to the cancer community?  

Were there shorts in the stock that needed to cover? 

@hoffmann6383 @ham59591shorts @FlyEaglesFly529 @JohnnyTabacco  $NWBO